Navigation Links
Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology
Date:12/11/2007

tta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, and the timing of launch of Rosetta's first diagnostic products constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing it
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
9. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... to biotechnology firms has revealed early bottlenecks on ... the researchers suggest that better communication of basic ... to faster commercialization down the road. , Biopharmaceutical ... university laboratories and licensed to biotechnology firms. Bottlenecks ... a high failure rate. But a new study ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2
... ... as Of Counsel in its Intellectual Property Group and will be practicing primarily out of ... matters. , ... January 13, 2010 -- Today Preti Flaherty announced that Wayne Keown ...
... , 18-year track ... companies, including cellulosic ethanol pioneer Verenium Corporation , ... Inc., a leading developer of second-generation technology solutions for the ... today that John McCarthy has joined the company ...
... , ST. LOUIS , Jan. 13 ... Group (Nasdaq: SIAL ), today announced the completion of an ... and logistics facility in Steinheim, Germany . The dedicated food-grade ... of Baking) audit, supports customers in Europe and ...
Cached Biology Technology:Attorney Wayne Keown Joins Preti Flaherty's Portland, ME Office 2Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer 2Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer 3SAFC(R) Enhances World-Class European Storage, Packaging and Distribution Facility to Further Support Food-Grade Certified Products 2SAFC(R) Enhances World-Class European Storage, Packaging and Distribution Facility to Further Support Food-Grade Certified Products 3SAFC(R) Enhances World-Class European Storage, Packaging and Distribution Facility to Further Support Food-Grade Certified Products 4
(Date:8/22/2014)... release is available in French . ... of essential nutrients from African soils looming as a major ... released today finds that over the last five years, 1.7 ... that have rejuvenated 1.6 million hectares and helped them double ... Alliance for a Green Revolution in Africa (AGRA) focuses on ...
(Date:8/22/2014)... to important discoveries in basic and clinical research ... mobilized into a complex offensive spanning multiple fronts. ... chemistry lab could help find new and more ... compound that targets a specific enzyme overexpressed in ... cells from brain tumours. , Chemistry professor Christopher ...
(Date:8/22/2014)... multifunctional enzyme that localizes to the ... cholesterol-synthesizing activities. DHCR24 overexpression confers neuroprotection ... deposition. Dr. Xiuli Lu and colleagues ... two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc and Ad-hSYN1-DHCR24-myc) ... neuronal cells. They also found that ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... WASHINGTON, DC A new analysis by the ... that the U.S. government has spent around $430 million ... the Department of Energy funding a majority of the ... European Union and three individual European countries the ...
... of dust and pollen in the atmosphere may make your ... in clouds, Colorado State University atmospheric scientists have discovered for ... to form precipitation in clouds is linked to the abundance ... study by Paul DeMott and Anthony Prenni, research scientists in ...
... If you think of diabetes onset like an elaborate ... Jolla Institute scientist has unmasked a previously unknown cellular player, ... is a hallmark of both type 1 and type 2 ... Jolla Institute for Allergy & Immunology, who led the team, ...
Cached Biology News:Amount of dust, pollen matters for cloud precipitation, climate change 2Amount of dust, pollen matters for cloud precipitation, climate change 3La Jolla Institute scientist leads team which discovers important new player in diabetes onset 2La Jolla Institute scientist leads team which discovers important new player in diabetes onset 3La Jolla Institute scientist leads team which discovers important new player in diabetes onset 4
... FastPlax Antibody is used to detect the ... surface of infected cells as early as ... of the FastPlax Titer Kit, which allows ... hours. The FastPlax Antibody can ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: